Compare First Horizon Corporation Common Stock (FHN) vs Heron Therapeutics Inc (HRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
First Horizon Corporation Common Stock vs Heron Therapeutics Inc — how do they compare? First Horizon Corporation Common Stock trades at $22 (market cap $10.74B), while Heron Therapeutics Inc trades at $0.36 (market cap $70.25M). The key difference: First Horizon Corporation Common Stock is far larger — about 152.9× Heron Therapeutics Inc's market cap, and First Horizon Corporation Common Stock pays a 3% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold First Horizon Corporation Common Stock for 0 Days and Heron Therapeutics Inc for 36 Days on average.
| FHN | HRTX | |
|---|---|---|
Market Cap | $10.74B | $70.25M |
Volume | 11,773,440 | 2,092,253 |
Sector | Financials | Health |
52-Week High | $26.23 | $1.49 |
52-Week Low | $19.94 | $0.27 |
Typical Hold Time | 0 Days | 36 Days |
Enterprise Value | $14.03B | $176.99M |
Dividend Yield | 3% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
First Horizon (FHN) trades at $22.77, down 1.26% on the day, with a neutral technical outlook. The stock shows strong fundamentals, including a P/E of 10.95 and net income margin of 30.87% for 2026, supported by three consecutive quarterly earnings beats. Recent news highlights executive recognitions and upcoming Q3 2026 earnings on October 15, 2026.
The outlook is positive given robust profitability, analyst consensus price target of $27.44 (20.5% upside), and no sell ratings. Risks include high debt-to-asset ratio of 1.81 and macroeconomic sensitivity. Earnings growth remains the key catalyst for further upside, with investor focus on Q3 results.
HRTX trades at $0.3906, down 6.02% on the day, with a bullish technical signal from moving averages and ADX indicators. The company reported a net loss of $20.20 million on $154.90 million revenue in 2025, with a negative net income margin of -22.52%. Recent Q2 2026 earnings missed expectations, posting a loss of $0.03 per share versus an expected loss of $0.005. Analyst consensus remains strongly positive with 17 buy ratings out of 19 total.
The outlook is mixed; strong analyst support and improving cash flow trends in 2026 suggest potential, but persistent losses and high valuation multiples like EV/EBITDA of 34.03 pose significant risks. Investment opportunity hinges on future profitability, while key risks include execution challenges and competitive pressures in the biotechnology sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About First Horizon Corporation Common Stock
First Horizon Corporation is the holding company for First Horizon Bank, a regional financial services provider operating roughly 460 branches across 11 states in southeastern US. It offers commercial, consumer, private banking, wealth management, and capital markets services.
Read more on FHN →About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →
